2024-10-18 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-saving medicines for patients with serious diseases.

**1. Performance Comparison:**

* **Cumulative return:** 92.09% (REGN) vs. 136.93% (VOO)
* **Current Lag:** -44.84% (Relative Lag: 31.65%) 
    * This means that REGN has underperformed VOO by 44.84% since the starting point of the data, but its relative lag is at the 31.65th percentile of its historical range.

**2. Recent Price Movement:**

* **Closing Price:** 1007.96
* **5-day Moving Average:** 1010.91
* **20-day Moving Average:** 1039.67
* **60-day Moving Average:** 1106.25

**3. Technical Indicators:**

* **RSI:** 38.96 (Neutral) - The RSI suggests the stock is currently in a neutral position, neither overbought nor oversold. 
* **PPO:** 0.05 (Neutral) -  The PPO indicates a neutral trend, suggesting a possible sideways movement or a consolidation period.
* **Delta_Previous_Relative_Divergence:** -25.9 (Short-term bearish) - The negative value indicates a short-term downward trend in the stock's relative strength.
* **Expected Return:** 0.0% - This represents the maximum expected return over the next 5 years, considering the current investment amount, and it indicates a potential underperformance compared to VOO.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report for Q2 2024 showed that REGN surpassed analysts' expectations, with EPS coming in at $13.25, exceeding estimates of $12.50. Revenue also exceeded expectations, reaching $3.55 billion compared to projected $3.4 billion.

**5. News and Recent Issues:**

Recent market sentiment towards REGN is generally positive, with analysts expecting continued growth in the company's key franchises. 

* **Performance Highlights:** REGN's key growth driver is its Eylea franchise, a treatment for age-related macular degeneration and other eye diseases. Eylea continues to demonstrate strong market share and growth potential. 
* **Analyst Opinions:** Despite the recent underperformance against VOO, many analysts remain optimistic about REGN's long-term prospects. This optimism stems from the company's robust pipeline of promising new treatments, particularly in the areas of oncology and inflammatory diseases. 

**6. Summary:**

REGN has underperformed the S&P 500 (VOO) in the recent past, but its current relative lag is within a normal range. Despite the recent underperformance,  REGN has shown strong recent earnings results, exceeding analysts' expectations. The company continues to demonstrate growth in its key franchises, with a robust pipeline of promising new treatments that could drive future growth. Technical indicators suggest a neutral to bearish trend, while the expected return is currently estimated at 0%. 

**7. Conclusion:**

While REGN has faced some challenges in recent months, its fundamental strengths, strong earnings performance, and promising pipeline of new treatments suggest a potential for future growth. However, investors should closely monitor the company's progress in developing its new therapies, and the overall market sentiment towards the biotechnology sector. 
